Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 3:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 318 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Hair Loss Clear all
Terminated Phase 4 Interventional Results available

Needle-free Delivery of Intralesional Triamcinolone for Pediatric Alopecia Areata

NCT05278858
View directory record Official record
Conditions
Alopecia Areata
Interventions
MedJet Device with intralesional triamcinolone
Combination Product
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
6 Years to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 30, 2024 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Treatment of Androgenetic Alopecia in Males and Females

NCT01437163
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
TopHat 655 rejuvenation system, Laser and/or Light Hair Rejuvenation System
Device
Lead sponsor
Apira Science, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
88 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
4
States / cities
Hoboken, New Jersey • New York, New York • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Sep 5, 2026, 3:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

A Study of Vitamin D in Subjects With Alopecia Areata

NCT01328678
View directory record Official record
Conditions
Alopecia Areata
Interventions
Not listed
Lead sponsor
Avera McKennan Hospital & University Health Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jul 7, 2011 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Results available

Study To Evaluate The Efficacy Of Tofacitinib In Moderate To Severe Alopecia Areata, Totalis And Universalis

NCT02299297
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tofacitinib
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia Areata

NCT02684097
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tralokinumab, Placebo
Drug
Lead sponsor
Emma Guttman
Other
Eligibility
18 Years to 75 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 6, 2020 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)

NCT01451138
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal and epidermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
4
States / cities
Birmingham, Alabama • Tucson, Arizona • Pinellas Park, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2013 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Not applicable Interventional

A Bioequivalence Study With Clinical Endpoints Comparing Generic Imiquimod Cream, 3.75% and Zyclara™ (Imiquimod) Cream, 3.75% in Subjects With Actinic Keratoses

NCT01502020
View directory record Official record
Conditions
Actinic Keratoses
Interventions
imiquimod cream, 3.75%, Vehicle Cream
Drug
Lead sponsor
Actavis Mid-Atlantic LLC
Industry
Eligibility
18 Years and older
Enrollment
410 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Birmingham, Alabama • Miami, Florida • Newnan, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2011 · Synced Sep 5, 2026, 3:40 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

NCT00999557
View directory record Official record
Conditions
Alopecia, Breast Cancer
Interventions
bimatoprost ophthalmic solution, placebo
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2016
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 30, 2020 · Synced Sep 5, 2026, 3:40 PM EDT
Recruiting No phase listed Observational

Blood Specimen Collection For Laboratory Assay Research

NCT06046651
View directory record Official record
Conditions
General; Metabolic Disorder, Sexual Dysfunction, Hair Loss, Pathology
Interventions
Not listed
Lead sponsor
Roman Health Ventures Inc.
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Timeline
2023 – 2033
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Phase 2Phase 3 Interventional Results available

PF-06651600 for the Treatment of Alopecia Areata

NCT03732807
View directory record Official record
Conditions
Alopecia Areata
Interventions
PF-06651600 Induction Dose, PF-06651600 Maintenance Dose #1, PF-06651600 Maintenance Dose #2, PF-06651600 Maintenance Dose #3, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
46
States / cities
Birmingham, Alabama • Beverly Hills, California • Irvine, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2022 · Synced Sep 5, 2026, 3:40 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

24 Week Clinical Trial to Evaluate Safety and Effectiveness of a Hair Growth System to Treat Male and Female Baldness

NCT01686295
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
iRestore Hair Rejuvenation System, sham device
Device
Lead sponsor
Freedom Laser Therapy, Inc.
Industry
Eligibility
25 Years to 60 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 17, 2012 · Synced Sep 5, 2026, 3:40 PM EDT
Enrolling by invitation Not applicable Interventional

To Test the Effectiveness and Implementation Approach of a 3-month PILI Pasifika Program Lifestyle Program With Components of Social Determinants of Health Activities in Real-world Settings (Clinical and Non-clinical Settings) Across 3 Years

NCT07387393
View directory record Official record
Conditions
Cardiometabolic Conditions, Hypertension (HTN), Dyslipidemia, Pre-diabetes, Type 2 Diabetes Mellitus (T2DM), Overweight (BMI > 25), Weight Loss Trial
Interventions
PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Phase 1 Interventional

Local Pharmacokinetics and Tolerability of Bimatoprost Applied to the Scalp of Male Patients With Androgenetic Alopecia

NCT02848300
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
Bimatoprost 1% Formulation A, Bimatoprost 1% Formulation B
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years to 49 Years · Male only
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 25, 2016 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Follicular Revival in Treatment-resistant Alopecia Areata: Evaluating Use of Micro-needling

NCT04338295
View directory record Official record
Conditions
Alopecia Areata
Interventions
Tattoo machine (SOL Nova Device)
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Male only
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 8, 2022 · Synced Sep 5, 2026, 3:40 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Investigation of Anatomical Correlates of Speech Discrimination

NCT01781039
View directory record Official record
Conditions
Sensorineural Hearing Loss
Interventions
Hearing Aid fitting
Device
Lead sponsor
Steward St. Elizabeth's Medical Center of Boston, Inc.
Other
Eligibility
18 Years to 100 Years
Enrollment
186 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 11, 2026 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Early Phase 1 Interventional

Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia

NCT03346668
View directory record Official record
Conditions
Scarring Alopecia, Frontal Fibrosing Alopecia, Lichen Planopilaris, Central Centrifugal Cicatricial Alopecia, Central Centrifugal Scarring Alopecia
Interventions
Topical gabapentin
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 24, 2024 · Synced Sep 5, 2026, 3:40 PM EDT
Completed No phase listed Observational

Natural History and Pathogenesis of Alopecia in Children and Adults

NCT05502796
View directory record Official record
Conditions
Hair Loss
Interventions
Not listed
Lead sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
NIH
Eligibility
2 Years to 120 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Sep 5, 2026, 3:40 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2023 · Synced Sep 5, 2026, 3:40 PM EDT
Recruiting Phase 3 Interventional

A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata

NCT06873945
View directory record Official record
Conditions
Alopecia Areata
Interventions
Ritlecitinib 100 mg, Ritlecitinib 50 mg, Placebo - 100 mg, Placebo - 50 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
1,330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
60
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Brea, California + 39 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 5, 2026, 3:40 PM EDT
Withdrawn Phase 2 Interventional

A Study of JNJ-64304500 in Participants With Alopecia Areata

NCT04740970
View directory record Official record
Conditions
Alopecia Areata
Interventions
JNJ-64304500, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
9
States / cities
Tampa, Florida • Plainfield, Indiana • Louisville, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Results available

Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

NCT05368103
View directory record Official record
Conditions
Alopecia Areata
Interventions
Daxdilimab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Hot Springs, Arkansas • Fountain Valley, California • Tampa, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 6, 2025 · Synced Sep 5, 2026, 3:40 PM EDT
Recruiting Phase 3 Interventional

Study to Evaluate the Efficacy and Safety of Deuruxolitinib in Adolescents With Severe Alopecia Areata

NCT07133308
View directory record Official record
Conditions
Alopecia Areata
Interventions
Deuruxolitinib, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 17 Years
Enrollment
355 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
54
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bryant, Arkansas + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Sep 5, 2026, 3:40 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

A 6-month, Randomized, Double-blind, Placebo Controlled Study Evaluating the Efficacy and Safety of USPlus DERM to Promote Hair Growth in Men and Women With Self-perceived Thinning Hair.

NCT06920758
View directory record Official record
Conditions
Thinning Hair
Interventions
USPlus DERM Bioactive Fatty Acids 160 mg Softgels, Placebo softgel
Dietary Supplement · Other
Lead sponsor
Ablon Skin Institute Research Center
Other
Eligibility
25 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Manhattan Beach, California
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 5, 2026, 3:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate and Compare Injections of Autologous Dermal Cells Into the Balding Scalp of Subjects With Hair Loss

NCT01451099
View directory record Official record
Conditions
Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
Interventions
Autologous cultured dermal cells
Biological
Lead sponsor
Aderans Research Institute
Industry
Eligibility
18 Years to 65 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
6
States / cities
Atlanta, Georgia • Chevy Chase, Maryland • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2012 · Synced Sep 5, 2026, 3:40 PM EDT